| Literature DB >> 35031671 |
Jeong Woo Yoo1, Kyo Chul Koo1, Byung Ha Chung1, Kwang Suk Lee2.
Abstract
We analyzed the intensity of pain at each site of systemic prostate biopsy (SBx) and compared the intensity of pain among magnetic resonance (MRI)-targeted transrectal biopsies according to the periprostatic nerve block (PNB) site. We collected data from 229 consecutive patients who had undergone MRI-targeted biopsy. Patients were stratified into two groups according to the site of PNB (base versus base and apex PNB). Pain was quantified at the following time points: probe insertion, injection at the prostate base, injection at the prostate apex, MRI cognitive biopsy (CBx), MRI/transrectal ultrasound fusion biopsy (FBx), SBx, and 15 min after biopsy. For all biopsy methods, the average pain were significantly higher in the base PNB group than in the base and apex PNB group (CBx, p < 0.001; FBx, p = 0.015; SBx, p < 0.001). In the base and apex PNB group, FBx was significantly more painful than SBx (p = 0.024). Overall, regardless of the PNB site, pain at the anterior sites was more than that at the posterior sites in FBx (p = 0.039). Base and apex PNB provided better overall pain control than base-only PNB in all biopsy methods. In the base and apex PNB group, FBx was more painful than CBx and SBx.Entities:
Mesh:
Year: 2022 PMID: 35031671 PMCID: PMC8760249 DOI: 10.1038/s41598-022-04795-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics of groups according to the site of the PNB.
| Base | Base and apex | ||
|---|---|---|---|
| N | 110 (49.8) | 111 (50.2) | |
| Age (years) | 69.0 ± 8.2 | 68.86 ± 7.8 | 0.839 |
| PSA (ng/mL) | 8.14 (5.42–13.63) | 6.92 (4.78–10.23) | 0.181 |
| Prostate volume (mL) | 35.7 ± 16.1 | 37.0 ± 18.1 | 0.568 |
| History of prostate biopsy | 20 (18.2) | 12 (10.8) | 0.120 |
| 132 | 150 | < 0.001 | |
| 3 | 40 (30.3) | 34 (22.7) | |
| 4 | 47 (35.6) | 88 (58.7) | |
| 5 | 45 (34.1) | 28 (18.7) | |
| Prostate cancer detection rate | 85 (77.3) | 79 (71.2) | 0.299 |
| Prostate cancer detection on target | 90 (68.2) | 89 (59.3) | 0.124 |
| 0.132 | |||
| 1 | 15 (13.6) | 19 (17.1) | |
| ≥ 2 | 70 (63.6) | 60 (54.1) | |
| Periprostatic nerve block | 149.5 ± 47.2 | 160.0 ± 53.3 | 0.121 |
| Prostate biopsies | 285.8 ± 165.2 | 327.6 ± 367.5 | 0.277 |
| Vasovagal syncope | 1 (0.9) | 0 (0.0) | 0.316 |
| Allergic reaction | 0 (0.0) | 0 (0.0) | – |
| AUR | 0 (0.0) | 0 (0.0) | – |
| Urinary retention because of blood clot | 0 (0.0) | 0 (0.0) | – |
| Fever | 0 (0.0) | 0 (0.0) | – |
Data are expressed as number (%), mean ± standard deviation, and median (IQR range).
AUR acute urinary retention, ISUP International Society of Urological Pathology, IQR interquartile, PI-RADS prostate imaging-reporting and data system, PNB periprostatic nerve block, PSA prostate-specific antigen.
Mean VAS scores during prostate biopsy in patients according to the site of the PNB.
| VAS scores | Base | Base and apex | |
|---|---|---|---|
| Probe insertion | 3.91 ± 2.03 | 3.45 ± 2.47 | 0.501 |
| Injection at basea | 2.80 ± 1.86 | 2.92 ± 1.91 | 0.652 |
| Injection at apexb | 4.30 ± 2.33 | 4.75 ± 2.53 | 0.177 |
| CBxc | 4.06 ± 2.59 | 3.01 ± 2.26 | < 0.001 |
| FBxd | 3.91 ± 2.44 | 3.21 ± 2.39 | 0.015 |
| SBxe | 4.00 ± 2.66 | 2.88 ± 2.19 | < 0.001 |
| At 15 min post prostate biopsy | 0.15 ± 0.62 | 0.20 ± 0.85 | 0.598 |
Data are expressed as mean ± SD.
aMean and SD of VAS scores during prostate base injections.
bMean and SD of VAS scores during prostate apex injections.
cMean and SD of VAS scores for individual CBx.
dMean and SD of VAS scores for individual FBx.
eMean and SD of VAS scores for individual SBx.
CBx magnetic resonance imaging cognitive target prostate biopsy, FBx magnetic resonance imaging/transrectal ultrasound fusion targeted prostate biopsy, SBx prostate systemic biopsy, PNB periprostatic nerve block, SD standard deviation, VAS visual analog scale.
Figure 1Mean profile plot of VAS scores for each SBx. SBx systemic prostate biopsy, Lat lateral, Lt left, Med medial, Rt right, VAS visual analog scale.
Differences in mean VAS scores during various types of biopsies between the two groups according to biopsy sites.
| VAS pain scores | Anterior | Posterior | |
|---|---|---|---|
| CBx with base PNB | 4.58 ± 2.58 | 3.98 ± 2.59 | 0.292 |
| CBx with base and apex PNB | 3.59 ± 2.55 | 2.89 ± 2.14 | 0.155 |
| Overall CBx | 4.02 ± 2.59 | 3.42 ± 2.43 | 0.098 |
| FBx with base PNB | 4.87 ± 2.93 | 3.71 ± 2.26 | 0.069 |
| FBx with base and apex PNB | 3.72 ± 2.67 | 3.09 ± 2.30 | 0.177 |
| Overall FBx | 4.22 ± 2.82 | 3.39 ± 2.29 | 0.039 |
Data are expressed as mean ± SD.
CBx magnetic resonance imaging cognitive target prostate biopsy, FBx magnetic resonance imaging/transrectal ultrasound fusion targeted prostate biopsy, PNB periprostatic nerve block, SD standard deviation, VAS visual analog scale.
Figure 2Study cohort flow diagram. MRI magnetic resonance image, PNB periprostatic nerve block, TRUS transrectal ultrasound.